Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 3030-3045

  Freitas, Andiara E ^a,b,c   Egea, Javier ^c,d   Buendia, Izaskun ^c,d   Gómez Rangel, Vanessa ^c   Parada, Esther ^c,d   Navarro, Elisa ^c,d   Casas, Ana Isabel ^c,e   Wojnicz, Aneta ^d   Ortiz, José Avendaño ^d   Cuadrado, Antonio ^f   Ruiz Nuño, Ana ^d   Rodrigues, Ana Lúcia S ^b   Lopez, Manuela G ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c INSTITUTO TEÓFILO HERNANDO   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Agmatine; BDNF; Corticosterone; Depression; Nrf2

Indexed keywords

AGMATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; GLUTAMIC ACID; IMIPRAMINE; NORADRENALIN; SEROTONIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR NRF2; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CORTICOSTERONE;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; HIPPOCAMPAL CA1 REGION; IMMUNOFLUORESCENCE; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; NORADRENALIN BRAIN LEVEL; OPEN FIELD TEST; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SEROTONIN BRAIN LEVEL; SPLASH TEST; TAIL SUSPENSION TEST; WESTERN BLOTTING; WILD TYPE MOUSE; ANHEDONIA; ANIMAL; ANIMAL BEHAVIOR; BIOLOGICAL MODEL; C57BL MOUSE; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

AGMATINE; ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; BEHAVIOR, ANIMAL; BIOMARKERS; CORTICOSTERONE; DEPRESSION; FEMALE; HIPPOCAMPUS; IMIPRAMINE; MICE, INBRED C57BL; MICROGLIA; MODELS, BIOLOGICAL; NEURONAL PLASTICITY; NEUROTRANSMITTER AGENTS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84929439654     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9182-6     Document Type: Article

References (81)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593–602. doi:10.1001/archpsyc.62.6.593
2. Smith K (2014) Mental health: a world of depression. Nature 515:181. doi:10.1038/515180a
3. Carroll CGC, Mendels J (1976) Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 33:1039–1044. doi:10.1001/archpsyc.1976.01770090029002
4. Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464–468. doi:10.1016/j.tins.2008.06.006
5. Frodl T, O’Keane V (2013) How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis 52:24–37. doi:10.1016/j.nbd.2012.03.012
6. Maric NP, Adzic M (2013) Pharmacological modulation of HPA axis in depression—new avenues for potential therapeutic benefits. Psychiatr Danub 25:299–305
7. Bruhn TO, Plotsky PM, Vale WW (1984) Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: studies on the adrenocorticotropin response to ether stress and exogenous CRF. Endocrinology 114:57–62. doi:10.1210/endo-114-1-57
8. Papadimitriou A, Priftis KN (2009) Regulation of the hypothalamic-pituitary-adrenal axis. Neuroimmunomodulation 16:265–271. doi:10.1159/000216184
9. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005) Limbic system mechanisms of stress regulation: hypothalamo–pituitary–adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201–1213. doi:10.1016/j.pnpbp.2005.08.006
10. Myers B, McKlveen JM, Herman JP (2014) Glucocorticoid actions on synapses, circuits, and behavior: Implications for the energetics of stress. Front Neuroendocrinol 35:180–196. doi:10.1016/j.yfrne.2013.12.003
11. Lee AL, Ogle WO, Sapolsky RM (2002) Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4:117–128. doi:10.1034/j.1399-5618.2002.01144.x
12. Duman RS (2004) Neural plasticity: consequences of stress and actions of antidepressant treatment. Dialogues Clin Neurosci 6:157–169
13. McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009) A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 34:41–54
14. Popoli M, Yan Z, McEwen BS, Sanacora G (2011) The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13:22–37. doi:10.1038/nrn3138
15. Czéh B, Fuchs E, Flügge G (2013) Altered glial plasticity in animal models for mood disorders. Curr Drug Targets 14:1249–12461. doi:10.2174/1389450111314110005
16. Sanacora G, Banasr M (2013) From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 73:1172–1179. doi:10.1016/j.biopsych.2013.03.032
17. Smiałowska M, Szewczyk B, Woźniak M, Wawrzak-Wleciał A, Domin H (2013) Glial degeneration as a model of depression. Pharmacol Rep 65:1572–1579
18. Verkhratsky A, Rodríguez JJ, Steardo L (2013) Astrogliopathology: a central element of neuropsychiatric diseases? Neuroscientist 20:576–588. doi:10.1177/1073858413510208
19. Kong H, Zeng XN, Fan Y, Yuan ST, Ge S, Xie WP, Wang H, Hu G (2014) Aquaporin-4 knockout exacerbates corticosterone-induced depression by inhibiting astrocyte function and hippocampal neurogenesis. CNS Neurosci Ther 20:391–402. doi:10.1111/cns.12222
20. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24:27–53. doi:10.1007/s11011-008-9118-1
21. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785. doi:10.1016/j.neubiorev.2011.12.005
22. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K, Lipton SA (2006) Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci U S A 103:768–773. doi:10.1073/pnas.0505723102
23. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61–69. doi:10.1196/annals.1427.036
24. Jaiswal AK (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36:1199–1207. doi:10.1016/j.freeradbiomed.2004.02.074
25. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780. doi:10.1038/nrc1189
26. Turpaev KT (2013) Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biochemistry (Mosc) 78:111–126. doi:10.1134/S0006297913020016
27. Freitas AE, Egea J, Buendía I, Navarro E, Rada P, Cuadrado A, Rodrigues AL, López MG (2014a) Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line. Mol Neurobiol. In press. doi: 10.1007/s12035-014-8827-1
28. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313–322. doi:10.1006/bbrc.1997.6943
29. Lussier AL, Romay-Tallón R, Kalynchuk LE, Caruncho HJ (2011) Reelin as a putative vulnerability factor for depression: examining the depressogenic effects of repeated corticosterone in heterozygous reeler mice. Neuropharmacology 60:1064–1074. doi:10.1016/j.neuropharm.2010.09.007
30. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2013) Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65:29–38. doi:10.1016/j.neuropharm.2012.09.008
31. Freitas AE, Bettio LE, Neis VB, Moretti M, Ribeiro CM, Lopes MW, Leal RB, Rodrigues AL (2014) Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice. J Psychiatr Res 58:137–146. doi:10.1016/j.jpsychires.2014.07.024
32. Neis VB, Manosso LM, Moretti M, Freitas AE, Daufenbach J, Rodrigues AL (2014) Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration. Behav Brain Res 261:336–344. doi:10.1016/j.bbr.2013.12.038
33. Rosa PB, Ribeiro CM, Bettio LE, Colla A, Lieberknecht V, Moretti M, Rodrigues AL (2014) Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice. Pharmacol Biochem Behav 127:1–6. doi:10.1016/j.pbb.2014.10.003
34. Wong ML, Licinio J (2001) Research and treatment approaches to depression. Nat Rev Neurosci 2:343–351. doi:10.1038/35072566
35. Hammen C, Kim EY, Eberhart NK, Brennan PA (2009) Chronic and acute stress and the prediction of major depression in women. Depress Anxiety 26:718–723. doi:10.1002/da.20571
36. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367–370
37. Freitas AE, Budni J, Lobato KR, Binfaré RW, Machado DG, Jacinto J, Veronezi PO, Pizzolatti MG, Rodrigues AL (2010) Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 34:335–343. doi:10.1016/j.pnpbp.2009.12.010
38. Freitas AE, Machado DG, Budni J, Neis VB, Balen GO, Lopes MW, de Souza LF, Dafre AL, Leal RB, Rodrigues AL (2013) Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice. Behav Brain Res 237:176–184. doi:10.1016/j.bbr.2012.09.035
39. Freitas AE, Machado DG, Budni J, Neis VB, Balen GO, Lopes MW, de Souza LF, Veronezi PO, Heller M, Micke GA, Pizzolatti MG, Dafre AL, Leal RB, Rodrigues AL (2013) Antidepressant-like action of the bark ethanolic extract from Tabebuia avellanedae in the olfactory bulbectomized mice. J Ethnopharmacol 145:737–745. doi:10.1016/j.jep.2012.11.040
40. Freitas AE, Moretti M, Budni J, Balen GO, Fernandes SC, Veronezi PO, Heller M, Micke GA, Pizzolatti MG, Rodrigues AL (2013) NMDA receptors and the l-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice. J Med Food 16:1030–1038. doi:10.1089/jmf.2012.0276
41. Rodrigues AL, Rocha JB, Mello CF, Souza DO (1996) Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. Pharmacol Toxicol 79:150–156
42. Isingrini E, Camus V, Le Guisquet AM, Pingaud M, Devers S, Belzung C (2010) Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 5, e10404. doi:10.1371/journal.pone.0010404
43. González RR, Fernández RF, Vidal JL, Frenich AG, Pérez ML (2011) Development and validation of an ultra-high performance liquid chromatography-tandem mass-spectrometry (UHPLC-MS/MS) method for the simultaneous determination of neurotransmitters in rat brain samples. J Neurosci Methods 198:187–194. doi:10.1016/j.jneumeth.2011.03.023
44. Su F, Wang F, Zhu R, Li H (2009) Determination of 5-hydroxytryptamine, norepinephrine, dopamine and their metabolites in rat brain tissue by LC-ESI-MS-MS. Chromatographia 69:207–213
45. Zhu KY, Fu Q, Leung KW, Wong ZC, Choi RC, Tsim KW (2011) The establishment of a sensitive method in determining different neurotransmitters simultaneously in rat brains by using liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 879:737–742. doi:10.1016/j.jchromb.2011.02.011
46. Reis DJ, Regunathan S (1999) Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 881:65–80. doi:10.1111/j.1749-6632.1999.tb09343.x
47. Goracke-Postle CJ, Overland AC, Riedl MS, Stone LS, Fairbanks CA (2007) Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals. J Neurochem 102:1738–1748. doi:10.1111/j.1471-4159.2007.04647.x
48. Tabor CW, Tabor H (1984) Polyamines. Ann Rev Biochem 53:749–790
49. Seo S, Liu P, Leitch B (2011) Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience 192:28–36. doi:10.1016/j.neuroscience.2011.07.007
50. Reis DJ, Regunathan S (1998) Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 72:80–85
51. Reis DJ, Regunathan S (2000) Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21:187–193. doi:10.1016/S0165-6147(00)01460-7
52. Piletz JE, Aricioglu F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch B, Halaris A, Hong S, Lee JE, Li J, Liu P, Molderings GJ, Rodrigues AL, Satriano J, Seong GJ, Wilcox G, Wu N, Gilad GM (2013) Agmatine: clinical applications after 100 years in translation. Drug Discov Today 17–18:880–893. doi:10.1016/j.drudis.2013.05.017
53. Zhu MY, Wang WP, Cai ZW, Regunathan S, Ordway G (2008) Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain. Eur J Neurosci 27:1320–1332. doi:10.1111/j.1460-9568.2008.06104.x
54. Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL (2002) Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13:387–391
55. Zomkowski ADE, Rosa AO, Lin J, Santos AR, Calixto JB, Rodrigues ALS (2004) Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 1023:253–263
56. Zomkowski AD, Santos AR, Rodrigues AL (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381:279–283. doi:10.1016/j.brainres.2004.07.041
57. Freitas AE, Bettio LE, Neis VB, Santos DB, Ribeiro CM, Rosa PB, Farina M, Rodrigues AL (2014) Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuropsychopharmacol Biol Psychiatry 50:143–150. doi:10.1016/j.pnpbp.2013.12.012
58. Shopsin B (2013) The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychol 25:113–118. doi:10.1111/j.1601-5215.2012.00675.x
59. Jiang XZ, Li YF, Zhang YZ, Chen HX, Li J, Wang NP (2008) 5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine. Yao Xue Xue Bao 43:467–473
60. Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT (2009) Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 57:415–424. doi:10.1016/j.neuropharm.2009.06.035
61. Lipsky RH, Marini AM (2007) Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 1122:130–143. doi:10.1196/annals.1403.009
62. Greenberg ME, Xu B, Lu B, Hempstead BL (2009) New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 29:12764–12767. doi:10.1523/JNEUROSCI.3566-09.2009
63. Cunha C, Brambilla R, Thomas KL (2010) A simple role for BDNF in learning and memory? Front Mol Neurosci 3:1. doi:10.3389/neuro.02.001.2010
64. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20:127–150. doi:10.1007/s10787-011-0111-7
65. Martín-de-Saavedra MD, Budni J, Cunha MP, Gómez-Rangel V, Lorrio S, Del Barrio L, Lastres-Becker I, Parada E, Tordera RM, Rodrigues AL, Cuadrado A, López MG (2013) Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38:2010–2022. doi:10.1016/j.psyneuen.2013.03.020
66. Lee SY, Lee SJ, Han C, Patkar AA, Masand PS, Pae CU (2013) Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 46:224–235. doi:10.1016/j.pnpbp.2012.09.008
67. Lukic I, Mitic M, Djordjevic J, Tatalovic N, Bozovic N, Soldatovic I, Mihaljevic M, Pavlovic Z, Radojcic MB, Maric NP, Adzic M (2014) Lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. Neuropsychobiology 70:1–9. doi:10.1159/000362841
68. Zheng A, Li H, Cao K, Xu J, Zou X, Li Y, Chen C, Liu J, Feng Z (2015) Maternal hydroxytyrosol administration improves neurogenesis and cognitive function in prenatally stressed offspring. J Nutr Biochem 26:190–199. doi:10.1016/j.jnutbio.2014.10.006
69. Djordjevic J, Djordjevic A, Adzic M, Mitic M, Lukic I, Radojcic MB (2015) Alterations in the Nrf2-Keap1 signaling pathway and its downstream target genes in rat brain under stress. Brain Res 1602:20–31. doi:10.1016/j.brainres.2015.01.010
70. Gilad GM, Salame K, Rabey JM, Gilad VH (1996) Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 58:PL 41–PL 46
71. Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G (2012) Antioxidants as antidepressants: fact or fiction? CNS Drugs 26:477–490. doi:10.2165/11633190-000000000-00000
72. Tata DA, Anderson BJ (2010) The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: implications for hippocampal volume reductions in depression. Physiol Behav 99:186–193. doi:10.1016/j.physbeh.2009.09.008
73. Allen NJ (2014) Astrocyte regulation of synaptic behavior. Annu Rev Cell Dev Biol 30:439–463. doi:10.1146/annurev-cellbio-100913-013053
74. Bernardinelli Y, Muller D, Nikonenko I (2014) Astrocyte-synapse structural plasticity. Neural Plast 2014:232105. doi:10.1155/2014/232105
75. Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 14:1225–1236. doi:10.2174/13894501113149990156
76. Roman A, Kreiner G, Nalepa I (2013) Macrophages and depression—a misalliance or well-arranged marriage? Pharmacol Rep 65:1663–1672
77. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, Maier SF, Yirmiya R (2014) Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 19:699–709. doi:10.1038/mp.2013.155
78. Gadotti VM, Tibola D, Paszcuk AF, Rodrigues AL, Calixto JB, Santos AR (2006) Contribution of spinal glutamatergic receptors to the antinociception caused by agmatine in mice. Brain Res 1093:116–122. doi:10.1016/j.brainres.2006.03.087
79. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpció Boronat M, Trullas R, Villarroel A, Lerma J, García-Sevilla JÁ (1999) Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 127:1317–1326. doi:10.1038/sj.bjp.0702679
80. Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY (2006) Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 1084:210–216. doi:10.1016/j.brainres.2006.02.024
81. Zhu MY, Wang WP, Bissette G (2006) Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons. Neuroscience 141:2019–2027. doi:10.1016/j.neuroscience.2006.05.011